Article
Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone.
Frontiers in public health - 1 Jan 2021
Wang Yujia, Wu Guoyu, Li Ru, Luo Yingzhe, Huang Xingmei, He Lifang, Zhong Huihui, Xiong Shaoquan
Abstract excerpt
Objective: To explore the efficacy comparison between epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) combined with traditional Chinese medicine (TCM) and single EGFR-TKIs for advanced non-small cell lung cancer (NSCLC). Methods: A total of 91 NSCLC patients with EGFR mutation were divided into an experimental group and a control group (in a ratio of 2:1) to receive TCM and EGFR-TKIs (61...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
